

Leyre Mestre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/942870/publications.pdf>

Version: 2024-02-01

36
papers

2,019
citations

279701

23
h-index

345118

36
g-index

42
all docs

42
docs citations

42
times ranked

2424
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. <i>Pharmaceutics</i> , 2022, 14, 1420.	2.0	3
2	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. <i>Neurotherapeutics</i> , 2021, 18, 920-937.	2.1	18
3	Aging and neuroinflammation: Changes in immune cell responses, axon integrity, and motor function in a viral model of progressive multiple sclerosis. <i>Aging Cell</i> , 2021, 20, e13440.	3.0	4
4	2- α -Arachidonoylglycerol reduces chondroitin sulphate proteoglycan production by astrocytes and enhances oligodendrocyte differentiation under inhibitory conditions. <i>Glia</i> , 2020, 68, 1255-1273.	2.5	13
5	How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. <i>Gut Microbes</i> , 2020, 12, 1813532.	4.3	24
6	Involvement of Wnt7a in the role of M2c microglia in neural stem cell oligodendrogenesis. <i>Journal of Neuroinflammation</i> , 2020, 17, 88.	3.1	20
7	Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 34.	1.8	23
8	Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. <i>Neurobiology of Disease</i> , 2020, 143, 104994.	2.1	18
9	A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. <i>Cells</i> , 2020, 9, 906.	1.8	31
10	Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1374.	2.2	35
11	2- α -AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. <i>Glia</i> , 2018, 66, 1447-1463.	2.5	40
12	Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. <i>Journal of Neuroinflammation</i> , 2018, 15, 64.	3.1	44
13	2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination. <i>Journal of Neuroscience</i> , 2017, 37, 8385-8398.	1.7	47
14	Microglia activation states and cannabinoid system: Therapeutic implications. , 2016, 166, 40-55.		127
15	Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System. <i>Current Pharmaceutical Design</i> , 2014, 20, 4707-4722.	0.9	69
16	Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	5
17	Viral models of multiple sclerosis: Neurodegeneration and demyelination in mice infected with Theiler's virus. <i>Progress in Neurobiology</i> , 2013, 101-102, 46-64.	2.8	78
18	Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. <i>Neuroscience Letters</i> , 2012, 508, 67-72.	1.0	13

#	ARTICLE	IF	CITATIONS
19	A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 1002-1016.	2.1	119
20	CD200â€CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. <i>Glia</i> , 2012, 60, 1437-1450.	2.5	113
21	Chemical Probes for the Recognition of Cannabinoid Receptors in Native Systems. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 6896-6899.	7.2	37
22	The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 736-749.	2.0	63
23	Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1receptors. <i>Journal of Neuroinflammation</i> , 2011, 8, 102.	3.1	51
24	Anandamide enhances ILâ€10 production in activated microglia by targeting CB₂ receptors: Roles of ERK1/2, JNK, and NFâ€PB. <i>Glia</i> , 2010, 58, 135-147.	2.5	149
25	A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. <i>Biochemical Pharmacology</i> , 2009, 77, 86-100.	2.0	85
26	Chapter 9 The Endocannabinoid Anandamide. <i>Vitamins and Hormones</i> , 2009, 81, 207-230.	0.7	19
27	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. <i>European Journal of Neuroscience</i> , 2008, 28, 633-641.	1.2	103
28	Therapeutic potential of CB2 targeting in multiple sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 185-195.	1.5	37
29	Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E2. <i>Biochemical Journal</i> , 2008, 409, 761-770.	1.7	40
30	Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis. <i>NeuroImmunoModulation</i> , 2007, 14, 182-187.	0.9	20
31	Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. <i>Molecular and Cellular Neurosciences</i> , 2007, 34, 551-561.	1.0	103
32	The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. <i>Biochemical Pharmacology</i> , 2006, 72, 869-880.	2.0	51
33	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. <i>Journal of Neurochemistry</i> , 2005, 92, 1327-1339.	2.1	131
34	Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. <i>British Journal of Pharmacology</i> , 2005, 145, 441-448.	2.7	114
35	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2005, 20, 207-217.	2.1	131
36	The Role of Cannabinoid System on Immune Modulation: Therapeutic Implications on CNS Inflammation. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 671-675.	1.1	33